BDNF and Creatine-Phosphate System

Could the real breakthrough in neuropsychiatric therapy emerge not from another molecule, but from integrating epigenetic regulation with brain bioenergetics?Could BDNF gene methylation shape how the brain responds to creatine? And more importantly, could epigenetic biomarkers help us tailor metabolic interventions with greater precision?By bringing together gene regulation, cellular energy metabolism, and neuropharmaceutical innovation, we propose a shift in paradigm, moving beyond siloed approaches toward an integrated, translational, precision-driven model of care.The real question is: are we ready to view synaptic plasticity and metabolic energy as components of the same therapeutic axis?The future of applied neuroscience may well depend on embracing this convergence.